JAHA:肾脏疾病与COVID-19患者结局之间的关联

2021-06-11 MedSci原创 MedSci原创

COVID-19住院患者AKI与主要不良心血管事件和全因死亡率之间存在显著的相关性。

最新的证据将COVID-19患者急性肾损伤(AKI)与更高的死亡率和呼吸系统发病率联系起来,但尚未在该人群中报告AKI与血管疾病结局之间的关系。

近日,心血管疾病领域权威杂志JAHA上发表了一篇研究文章,研究人员旨在试图评估COVID-19住院患者慢性肾脏病 (CKD)、AKI 与死亡率和心血管结局之间的关联。

大型多中心登记中心纳入了来自88家医院的8574名COVID-19患者,研究人员收集了参与者住院期间的基线特征和实验室检查数据。该研究的主要暴露指标包括CKD(分类为无CKD、CKD和终末期肾病)和AKI(分类为无AKI或1、2 或3期AKI)。该研究的主要结局为全因死亡率。关键的次要结局是主要心脏不良事件,定义为心血管死亡、非致死性卒中、非致死性心肌梗死、新发非致死性心力衰竭和非致死性心源性休克。

主要结局森林图

经多变量调整后,CKD和终末期肾病与死亡率或主要不良心脏事件无关。相比之下,AKI与死亡率(与无AKI相比,1期AKI的风险比 [HR]为1.72[95%CI为1.46-2.03];2期AKI的HR为1.83 [95%CI为1.52-2.20];3期AKI的HR为1.69 [95%CI为1.44-1.98])和主要不良心脏事件(与无AKI相比,1期AKI的HR为2.17[95%CI为1.74-2.71];2期AKI的HR,2.70 [95%CI为2.07-3.51];3期AKI的HR为3.06 [95%CI为2.52-3.72])。

这项大型研究表明,COVID-19住院患者AKI与主要不良心血管事件和全因死亡率之间存在显著的相关性

原始出处:

Anjali Rao.et al.Association of Kidney Disease With Outcomes in COVID‐19: Results From the American Heart Association COVID‐19 Cardiovascular Disease Registry.J AM HEART ASSOC.2021.https://www.ahajournals.org/doi/full/10.1161/JAHA.121.020910

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=976670, encodeId=bd6a9e667039, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a272265480, createdName=12192b1am98暂无昵称, createdTime=Fri Jun 25 00:09:28 CST 2021, time=2021-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=974690, encodeId=3ffd9e4690d4, content=很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210618/990130e8fda8417597daa66a45608625/78d1a596e4624fae9a0acbf271f8612c.jpg, createdBy=4a742354206, createdName=飞天映雪, createdTime=Fri Jun 18 17:06:09 CST 2021, time=2021-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=974689, encodeId=73ef9e468977, content=哈哈, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210618/990130e8fda8417597daa66a45608625/78d1a596e4624fae9a0acbf271f8612c.jpg, createdBy=4a742354206, createdName=飞天映雪, createdTime=Fri Jun 18 17:06:06 CST 2021, time=2021-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268554, encodeId=22ae1268554e1, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Sun Jun 13 10:39:27 CST 2021, time=2021-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297532, encodeId=83b3129e5324c, content=<a href='/topic/show?id=c0385134ab' target=_blank style='color:#2F92EE;'>#COVID-19患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5134, encryptionId=c0385134ab, topicName=COVID-19患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6976269, createdName=zhangph, createdTime=Sun Jun 13 10:39:27 CST 2021, time=2021-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480041, encodeId=4cfd1480041d4, content=<a href='/topic/show?id=f9e0530e169' target=_blank style='color:#2F92EE;'>#患者结局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53071, encryptionId=f9e0530e169, topicName=患者结局)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Sun Jun 13 10:39:27 CST 2021, time=2021-06-13, status=1, ipAttribution=)]
    2021-06-25 12192b1am98暂无昵称

    学习了

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=976670, encodeId=bd6a9e667039, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a272265480, createdName=12192b1am98暂无昵称, createdTime=Fri Jun 25 00:09:28 CST 2021, time=2021-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=974690, encodeId=3ffd9e4690d4, content=很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210618/990130e8fda8417597daa66a45608625/78d1a596e4624fae9a0acbf271f8612c.jpg, createdBy=4a742354206, createdName=飞天映雪, createdTime=Fri Jun 18 17:06:09 CST 2021, time=2021-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=974689, encodeId=73ef9e468977, content=哈哈, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210618/990130e8fda8417597daa66a45608625/78d1a596e4624fae9a0acbf271f8612c.jpg, createdBy=4a742354206, createdName=飞天映雪, createdTime=Fri Jun 18 17:06:06 CST 2021, time=2021-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268554, encodeId=22ae1268554e1, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Sun Jun 13 10:39:27 CST 2021, time=2021-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297532, encodeId=83b3129e5324c, content=<a href='/topic/show?id=c0385134ab' target=_blank style='color:#2F92EE;'>#COVID-19患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5134, encryptionId=c0385134ab, topicName=COVID-19患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6976269, createdName=zhangph, createdTime=Sun Jun 13 10:39:27 CST 2021, time=2021-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480041, encodeId=4cfd1480041d4, content=<a href='/topic/show?id=f9e0530e169' target=_blank style='color:#2F92EE;'>#患者结局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53071, encryptionId=f9e0530e169, topicName=患者结局)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Sun Jun 13 10:39:27 CST 2021, time=2021-06-13, status=1, ipAttribution=)]
    2021-06-18 飞天映雪

    很好

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=976670, encodeId=bd6a9e667039, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a272265480, createdName=12192b1am98暂无昵称, createdTime=Fri Jun 25 00:09:28 CST 2021, time=2021-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=974690, encodeId=3ffd9e4690d4, content=很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210618/990130e8fda8417597daa66a45608625/78d1a596e4624fae9a0acbf271f8612c.jpg, createdBy=4a742354206, createdName=飞天映雪, createdTime=Fri Jun 18 17:06:09 CST 2021, time=2021-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=974689, encodeId=73ef9e468977, content=哈哈, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210618/990130e8fda8417597daa66a45608625/78d1a596e4624fae9a0acbf271f8612c.jpg, createdBy=4a742354206, createdName=飞天映雪, createdTime=Fri Jun 18 17:06:06 CST 2021, time=2021-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268554, encodeId=22ae1268554e1, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Sun Jun 13 10:39:27 CST 2021, time=2021-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297532, encodeId=83b3129e5324c, content=<a href='/topic/show?id=c0385134ab' target=_blank style='color:#2F92EE;'>#COVID-19患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5134, encryptionId=c0385134ab, topicName=COVID-19患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6976269, createdName=zhangph, createdTime=Sun Jun 13 10:39:27 CST 2021, time=2021-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480041, encodeId=4cfd1480041d4, content=<a href='/topic/show?id=f9e0530e169' target=_blank style='color:#2F92EE;'>#患者结局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53071, encryptionId=f9e0530e169, topicName=患者结局)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Sun Jun 13 10:39:27 CST 2021, time=2021-06-13, status=1, ipAttribution=)]
    2021-06-18 飞天映雪

    哈哈

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=976670, encodeId=bd6a9e667039, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a272265480, createdName=12192b1am98暂无昵称, createdTime=Fri Jun 25 00:09:28 CST 2021, time=2021-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=974690, encodeId=3ffd9e4690d4, content=很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210618/990130e8fda8417597daa66a45608625/78d1a596e4624fae9a0acbf271f8612c.jpg, createdBy=4a742354206, createdName=飞天映雪, createdTime=Fri Jun 18 17:06:09 CST 2021, time=2021-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=974689, encodeId=73ef9e468977, content=哈哈, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210618/990130e8fda8417597daa66a45608625/78d1a596e4624fae9a0acbf271f8612c.jpg, createdBy=4a742354206, createdName=飞天映雪, createdTime=Fri Jun 18 17:06:06 CST 2021, time=2021-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268554, encodeId=22ae1268554e1, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Sun Jun 13 10:39:27 CST 2021, time=2021-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297532, encodeId=83b3129e5324c, content=<a href='/topic/show?id=c0385134ab' target=_blank style='color:#2F92EE;'>#COVID-19患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5134, encryptionId=c0385134ab, topicName=COVID-19患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6976269, createdName=zhangph, createdTime=Sun Jun 13 10:39:27 CST 2021, time=2021-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480041, encodeId=4cfd1480041d4, content=<a href='/topic/show?id=f9e0530e169' target=_blank style='color:#2F92EE;'>#患者结局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53071, encryptionId=f9e0530e169, topicName=患者结局)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Sun Jun 13 10:39:27 CST 2021, time=2021-06-13, status=1, ipAttribution=)]
    2021-06-13 zhaohui6731
  5. [GetPortalCommentsPageByObjectIdResponse(id=976670, encodeId=bd6a9e667039, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a272265480, createdName=12192b1am98暂无昵称, createdTime=Fri Jun 25 00:09:28 CST 2021, time=2021-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=974690, encodeId=3ffd9e4690d4, content=很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210618/990130e8fda8417597daa66a45608625/78d1a596e4624fae9a0acbf271f8612c.jpg, createdBy=4a742354206, createdName=飞天映雪, createdTime=Fri Jun 18 17:06:09 CST 2021, time=2021-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=974689, encodeId=73ef9e468977, content=哈哈, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210618/990130e8fda8417597daa66a45608625/78d1a596e4624fae9a0acbf271f8612c.jpg, createdBy=4a742354206, createdName=飞天映雪, createdTime=Fri Jun 18 17:06:06 CST 2021, time=2021-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268554, encodeId=22ae1268554e1, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Sun Jun 13 10:39:27 CST 2021, time=2021-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297532, encodeId=83b3129e5324c, content=<a href='/topic/show?id=c0385134ab' target=_blank style='color:#2F92EE;'>#COVID-19患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5134, encryptionId=c0385134ab, topicName=COVID-19患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6976269, createdName=zhangph, createdTime=Sun Jun 13 10:39:27 CST 2021, time=2021-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480041, encodeId=4cfd1480041d4, content=<a href='/topic/show?id=f9e0530e169' target=_blank style='color:#2F92EE;'>#患者结局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53071, encryptionId=f9e0530e169, topicName=患者结局)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Sun Jun 13 10:39:27 CST 2021, time=2021-06-13, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=976670, encodeId=bd6a9e667039, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a272265480, createdName=12192b1am98暂无昵称, createdTime=Fri Jun 25 00:09:28 CST 2021, time=2021-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=974690, encodeId=3ffd9e4690d4, content=很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210618/990130e8fda8417597daa66a45608625/78d1a596e4624fae9a0acbf271f8612c.jpg, createdBy=4a742354206, createdName=飞天映雪, createdTime=Fri Jun 18 17:06:09 CST 2021, time=2021-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=974689, encodeId=73ef9e468977, content=哈哈, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210618/990130e8fda8417597daa66a45608625/78d1a596e4624fae9a0acbf271f8612c.jpg, createdBy=4a742354206, createdName=飞天映雪, createdTime=Fri Jun 18 17:06:06 CST 2021, time=2021-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268554, encodeId=22ae1268554e1, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Sun Jun 13 10:39:27 CST 2021, time=2021-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297532, encodeId=83b3129e5324c, content=<a href='/topic/show?id=c0385134ab' target=_blank style='color:#2F92EE;'>#COVID-19患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5134, encryptionId=c0385134ab, topicName=COVID-19患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6976269, createdName=zhangph, createdTime=Sun Jun 13 10:39:27 CST 2021, time=2021-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480041, encodeId=4cfd1480041d4, content=<a href='/topic/show?id=f9e0530e169' target=_blank style='color:#2F92EE;'>#患者结局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53071, encryptionId=f9e0530e169, topicName=患者结局)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Sun Jun 13 10:39:27 CST 2021, time=2021-06-13, status=1, ipAttribution=)]

相关资讯

FDA发出警告:怀孕20周以后避免使用非甾体类抗炎药(NSAIDs),可导致婴儿肾脏疾病和羊水减少

未出生婴儿的羊水主要是由肾脏产生的,因此肾脏问题可能导致羊水含量降低,并引起并发症。

CLIN CHEM LAB MED:对硫酸吲哚酚试剂盒NIPRO的性能评价

目前,肾脏疾病与心血管疾病(CVD)之间的关系被称为心肾综合征。硫酸吲哚氧基是加速心肾综合征进展的尿毒症毒素之一。本报告提出了一种更简便的测量方法。

Eur Arch Otorhinolaryngol:慢性肾脏疾病中红细胞分布宽度与听力损伤相关

之前的研究表明,在患有炎症疾病的患者中,炎症标记与听力损伤相关。因此,对炎症情况的筛查对患有炎症参与者听力损失(HL)风险的预测是有价值的。因此,有研究人员使用了炎症状态间接预测因子-红细胞分布宽度(

Cell Metabolism: 重大进展!山东大学易凡团队鉴定了糖尿病性肾脏疾病的潜在治疗新靶点

足细胞中脂质的积累是糖尿病肾病(DKD)的主要决定因素,通过介导足细胞脂质代谢来鉴定潜在的治疗靶点具有临床重要性。

JACC:慢性肾脏疾病患者的心衰住院风险研究

目前,对于慢性肾脏疾病(CKD)相关的心衰住院率、重复住院率和心衰住院预后尚不清楚。本研究纳入分析了CRIC临床试验中的3791名CKD患者,心衰的住院率是5.8/100人年,与心衰伴射血分数降低患者相比,心衰伴保留型射血分数的患者住院率更高。调整后的心衰发生率在eGFR更低的患者的中更高。相似的,心衰的住院风险在尿白蛋白与肌酐比值更高的患者中更高。总体来看,有20.6%的患者在30天内右心衰的再

2019 ASH指南:镰状细胞病——心肺和肾脏疾病

2019年12月,美国血液病学会(ASH)发布了镰状细胞病指南——心肺和肾脏疾病的管理。终末期器官疾病的预防和管理是成人和儿童镰状细胞病(SCD)患者面临的主要调整,SCD患者心肺和肾脏疾病的筛查、诊断和管理的不确定性可可变性导致患者的不同结局。本文主要针对镰状细胞病患者心肺和肾脏并发症的筛查,诊断以及管理提出10条循证建议。对成人SCD以及静脉血栓栓塞患者的抗凝治疗时间也提出了建议。